



Contribution ID: 336

Type: Poster

## Production and quality control of $^{177}\text{Lu}$ for labelling

Thursday, 22 April 2010 12:00 (20 minutes)

Lutetium-177 is a radionuclide used in nuclear medicine for therapeutic application. Both  $\beta$  and  $\gamma$  radiations emitted from  $^{177}\text{Lu}$  allow imaging of the therapeutic radionuclide without need of adding any other radionuclide. It can be prepared in the nuclear reactor via direct ( $n, \gamma$ ) activation from enriched lutetium target or via indirect neutron activation from ytterbium oxide. In this case, carrier free  $^{177}\text{Lu}$  is prepared, however, separation from irradiated target is necessary.  $^{177}\text{Lu}$  decays with a half life of 6.7 days. The research was focused on development of the semi-automatic module for processing the neutron irradiated targets and on optimizing the conditions of production and quality control of the  $^{177}\text{Lu}$  radiopharmaceutical precursor.

Enriched lutetium oxide in 5 M nitric acid was put into the titanium vial and evaporated to dryness. The screwed and tightened vial was irradiated for 96 hours in LVR-15 nuclear reactor (reactor power 7-9 MW) at the approximate neutron flux of  $5 \times 10^{13} \text{ n.cm}^{-2}\text{s}^{-1}$ . The irradiated target was allowed to cool for two days and then processed using semi-automatic module. Titanium ampoules were opened and filled subsequently by four aliquots 0.5 – 1.5 mL of nitric acid 1 mol/L in order to dissolve irradiated target. All aliquots were collected, evaporated to dryness and re-dissolved with hydrochloric acid 0.01 mol/L. Final solution was passed through 0.22 mm filter and after dispensing, final solution was autoclaved for 20 minutes at 125°C. All production steps were operated using touch screen set-up on the front wall of the hot cell.

The radioactivity was measured by ionization chamber Atomlab 100. The radionuclidic purity was determined by  $\gamma$  spectrometry. The radiochemical purity was determined by radio-TLC with ITLC-SG strips as a solid phase. The method consisted of two steps: Test for insoluble and colloid forms –liquid phase 0.15 M NaCl in 0.02 M HCl and the test for lutetium organic forms –liquid phase mixture of  $\text{NH}_2\text{OH} : \text{CH}_3\text{OH} : \text{H}_2\text{O}$  (0.2 : 2 : 4). The gas-flow proportional counting tube (Minigita, Raytest) was used for detection. The pH was measured by microelectrode Hamilton Biotrode. Bacterial endotoxins test was carried out using kinetic turbidimetric methods. The chemical impurities of Ti and Fe were checked by ICP for couple of batches (external collaboration with Nuclear Research Institute Řež, plc.).

The specific activities of  $^{177}\text{Lu}$  at the end of irradiation ranged from 100 to 264 GBq/mg (2.9 to 7.1 Ci/mg), Specific activity of  $^{177}\text{Lu}$  at the time of production ranged from 61 to 86 GBq/mg (1.6-2.3 Ci/mg). The  $\gamma$ -spectrometric measurements showed the content of  $^{177}\text{Lu}$  at the level 0.005% at the time of production. Content of Ti ranged from 0.004 to 0.385  $\mu\text{g/GBq}$  of  $^{177}\text{Lu}$  and content of Fe ranged from 0.023 to 0.708  $\mu\text{g/GBq}$  of  $^{177}\text{Lu}$  at the time of production.

The semi-automatic elution device for production of  $^{177}\text{Lu}$  was developed, tested and the operation qualification was carried out. Manufacture process was validated on three batches of  $^{177}\text{Lu}$  product. Methods for quality control were verified and GMP compliance documentation is currently under preparation.

**Primary author:** Dr KROPACEK, Martin (Nuclear Physics Institute of the ASCR, 25068 Řež by Prague, Czech Republic)

**Co-authors:** MELICHAR, Frantisek (Nuclear Physics Institute of the ASCR, 25068 Rez by Prague, Czech Republic); PAVLIK, Jan (Nuclear Physics Institute of the ASCR, 25068 Rez by Prague, Czech Republic); SRANK, Jiri (Nuclear Physics Institute of the ASCR, 25068 Rez by Prague, Czech Republic); VENTRUBA, Jiri (Nuclear Physics Institute of the ASCR, 25068 Rez by Prague, Czech Republic); PROCHAZKA, Libor (Nuclear Physics Institute of the ASCR, 25068 Rez by Prague, Czech Republic); TOMES, Marek (Nuclear Physics Institute of the ASCR, 25068 Rez by Prague, Czech Republic)

**Presenter:** Dr KROPACEK, Martin (Nuclear Physics Institute of the ASCR, 25068 Rez by Prague, Czech Republic)

**Session Classification:** Poster Session - Nuclear Methods in Medicine, Radiopharmaceuticals, Labelled Compounds

**Track Classification:** Nuclear Methods in Medicine, Radiopharmaceuticals and Radiodiagnostics, Labelled Compounds